Merck's potential blockbuster cholesterol pill succeeds in late-stage studies
(Reuters) -Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines.
The company is searching for its next blockbuster candidate as its major revenue driver, Keytruda, is expected to lose patent protection by the end of the decade.
Merck's non-statin cholesterol drug, enlicitide decanoate, is being tested for the treatment of hyperlipidemia, a condition that causes elevated buildup of fat in the blood vessels and can lead to heart attacks and strokes.
Enlicitide works by blocking PCSK9, a protein that plays a crucial role in regulating cholesterol levels, while statins block an enzyme the liver uses to make cholesterol.
BMO Capital Markets analyst Evan Seigerman said Merck's drug could potentially provide a "multi-billion dollar opportunity" that expands the PCSK9 market beyond current injectable therapies.
The drug showed meaningful reductions in LDL-C cholesterol, commonly referred to as "bad cholesterol", when compared to placebo and other oral non-statin therapies, Merck said.
However, Leerink analysts have noted that Astrazeneca's AZD0780 is a "credible threat" as it has shown a 50.7% reduction in LDL-C levels during a trial.
Merck has not given the details on LDL-C reduction for enlicitide.
The drug was tested in patients who have a history of, or are at risk for a type of heart disease, and were treated with a statin.
Shares of Merck were up 2% in premarket trading.
Verve Therapeutics is also developing a gene therapy to reduce high cholesterol levels, which is expected to be used in combination with other drugs.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Merck's Cholesterol Medication Achieves Primary Endpoint in Two Trials
Merck & Co., Inc. (NYSE:MRK) is one of the best Dow stocks to invest in. On June 9, the company announced that its drug, enlicitide decanoate, achieved its primary goal of lowering a specific type of cholesterol in two late-stage clinical trials. A close-up of a person's hand holding a bottle of pharmaceuticals. The medication is being studied as a potential treatment for hyperlipidemia, a condition marked by high levels of fat in the bloodstream. According to the company, enlicitide led to significant reductions in LDL-C, or "bad" cholesterol, in patients with existing heart disease or those at risk of developing it. Merck & Co., Inc. (NYSE:MRK) is a global healthcare organization focused on providing innovative health solutions through its medicines, vaccines, biologic therapies, and animal health products. The stock has surged by over 1% in the past month. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
UK confirms case of bird flu in poultry in northern England
LONDON (Reuters) -Britain has detected a case of the H5N1 bird flu in poultry in West Yorkshire, northern England, the Department for Environment, Food and Rural Affairs said on Wednesday. "All poultry on the premises will be humanely culled," a notice on the department's website said.
New York Post
an hour ago
- New York Post
Hegseth wavers on Russia sanctions, says US should not use ‘every tool' to end Ukraine invasion
WASHINGTON — Defense Secretary Pete Hegseth resisted senators' efforts to secure his support for a bipartisan bill that would sanction Russia for its war on Ukraine, telling an Appropriations subcommittee Wednesday that the US should not use 'every tool at our disposal' to pressure Moscow to stop its assault. Asked by Sen. Chris Coons (D-Del.) whether Washington 'should use every tool it has at its disposal, including additional sanctions, to pressure Russia to come to the table to negotiate a just and lasting peace for the war in Ukraine,' Hegseth demurred. 'Senator, every tool at our disposal? No,' he said. 'We have a lot of tools in a lot of places.' 'We should be pursuing a cease-fire and a negotiated resolution to the war in Ukraine at any cost,' Coons responded. ''Peace through strength' means actually using our strength, continuing to support Ukraine, and securing a lasting peace. [Vladimir] Putin will only stop when we stop him.' 4 Defense Secretary Pete Hegseth testified Wednesday at a Senate Appropriations Committee hearing. REUTERS Prior to questioning Hegseth, Coons had talked up Sen. Lindsey Graham (R-SC) and Sen. Richard Blumenthal's (D-Conn.) pending bill to further sanction Russia for its continued resistance to peace in Ukraine. The legislation, backed by 80 senators, would impose sanctions on key Russian officials and economic sectors — and, critically, penalize foreign nations that do business with Moscow. Graham later followed up, urging Hegseth and the administration 'to use that tool to get the attention of China and India.' 'China buys — and India buys — 70% of Russia's oil … If they stop buying cheap Russian oil tomorrow, would that grind Putin's war machine to a halt?' Graham asked, later adding: 'We have an ability, through legislation, to get China and India's attention [and say] that if you keep buying cheap Russian oil to empower Putin to kill Ukrainian children, you're going to lose access to our markets. 'We're not going to evict every Russian from Ukraine, I'm a practical guy,' Graham added. 'But we got to end this war so we don't entice China to take Taiwan, and we don't encourage Iran to think we're just all talk [about] stopping their nuclear ambitions.' 4 Sen. Lindsey Graham (R-S.C.) questions Secretary of Defense Pete Hegseth during a Senate Committee on Appropriations subcommittee hearing to examine proposed budget estimates for fiscal year 2026 for the Department of Defense. AP On Friday, the Wall Street Journal reported that the White House was quietly pushing Graham to water down the bill by allowing waivers to exempt certain people and entities from sanctions and to 'remove the mandatory nature' of the legislation. A White House official told the outlet that the Constitution 'vests the president with the authority to conduct diplomacy with foreign nations.' 'Any sanction package must provide complete flexibility for the president to continue to pursue his desired foreign policy,' they added. Hegseth did admit Wednesday that Russia is the 'aggressor' in Ukraine and that Chinese President Xi Jinping wants Moscow to 'win' the conflict. However, the secretary declined to answer Sen. Mitch McConnell's (R-Ky.) question about 'which side' he wanted to win the war. 'As we've said time and time again, this president is committed to peace in that conflict,' Hegseth said. 'Ultimately, peace serves our national interests, and we think the interests of both parties, even if that outcome will not be preferable to many in this room and many in our country.' 4 Defense Secretary Pete Hegseth (R) greets Chairman of the Joint Chiefs of Staff Air Force Gen. Dan Caine before testifying during a hearing with the Senate Appropriations Committee on June 11. Getty Images McConnell pushed further, noting that the Russians 'don't seem to be too interested' in peace talks. The former Senate GOP leader also alleged that NATO partners increasing their defense spending at Trump's behest are now wondering 'whether we're in the midst of brokering what appears to be allowing the Russians to define victory.' 'I think victory is defined by the people that have to live there, the Ukrainians,' he said. 'And I don't think they're going to ever conclude that victory means basically adopting the Russian views on all this. ' Hegseth responded that 'no one's adopting views,' but added that the upcoming National Defense Authorization Act does not include funding of weapons for Ukraine because 'the budget reflects the reality that Europe needs to step up more for the defense of its own continent, and President Trump deserves the credit for that.' 4 Ranking member Sen. Chris Coons (D-Del.) speaks with subcommittee Chairman Sen. Mitch McConnell (R-KY) during a hearing with the Senate Appropriations Committee on June 11, 2025. Getty Images McConnell agreed, noting that he had 'the same complaints' about the Biden administration not pushing hard enough for Europe to fund Ukraine's defense. Still, the Kentuckian insisted that by not standing foursquare behind the Kyiv government, 'it seems to me pretty obvious that America's reputation is on the line.' 'Will we defend democratic allies against authoritarian aggressors?' McConnell asked. 'That's the international concern that I have about this, and I think a number of my fellow members share that view.'
